Atara Biotherapeutics building $55M CAR-T gene therapy plant in Southern California

Artist's rendering of Atara Biotherapeutics’ new ATOM CAR-T gene therapy manufacturing facility in Thousand Oaks, California. (Atara Biotherapeutics)

Atara Biotherapeutics has initiated construction of a new CAR-T gene therapy manufacturing facility in Thousand Oaks, California, where it will produce cells for allogeneic treatments.

Dubbed ATOM for Atara T-cell Operations and Manufacturing, the 90,000-square-foot facility will house manufacturing as well as R&D labs and office space.

The company estimates the final cost of the site to be between $50 million and $55 million, and it is projected to create about 100 new skilled jobs when completed in 2019.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Atara, which was founded in 2012, is currently in late-stage trials for what it calls tabelecleucel, or “tab-cel,” which is a potential treatment for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. 

Many CAR-T cell therapies, mainly focused on cancer treatments, are autologous cell therapies that take cells from a sick patient, modify them and then inject them back into the same patient. Cells for allogeneic treatments are harvested from donors matching a patient. While it can take weeks to turn around autologous therapies, allogeneic treatments can be available in several days.

The company recently released results of a midstage study with tab-cel used on 35 patients in whom Genentech’s Rituxan had failed. In that study, 68% of those patients who had a cell transplant and in whom Rituxan had failed were still alive after one year versus an expected 16 to 56 days. A second study included 14 patients who received a solid organ transplant; they had a median survival rate of 21.3 months versus an expected 12 to 13 months.


Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.